Retatrutide vs Semaglutide: How the Triple Agonist Compares
Metabolic peptide comparison
Retatrutide vs Semaglutide.
Semaglutide produced 14.9% mean body-weight reduction in the STEP-1 trial. Retatrutide produced 24.2% in a shorter Phase 2 trial. Here is how the two compounds differ mechanistically, and why the triple-agonist profile produces such different research outcomes.
Bottom line
Semaglutide is a GLP-1 monoagonist with FDA approval as Ozempic (diabetes) and Wegovy (obesity). Retatrutide is a triple GLP-1/GIP/glucagon agonist in active Phase 3 trials. The triple-receptor profile produces approximately 60% greater weight-loss magnitude in matched-duration trials, at the cost of more pronounced gastrointestinal side effects in the highest dose tiers.
Side-by-side comparison
| Retatrutide | Semaglutide |
Deep dive: Retatrutide
Retatrutide is a 39-amino-acid synthetic peptide developed by Eli Lilly that activates GLP-1, GIP, and glucagon receptors simultaneously. The triple-agonist profile combines insulin secretion enhancement (GLP-1), insulin sensitivity modulation (GIP), and energy expenditure increases (glucagon) into a single molecule.
The compound has a 6-day plasma half-life (similar to semaglutide), supporting once-weekly subcutaneous administration. Phase 2 obesity data published in NEJM (Jastreboff et al., 2023) showed 24.2% mean body-weight reduction at 48 weeks at the 12 mg dose tier.
Phase 3 trials are now in progress under the TRIUMPH program, evaluating obesity, type-2 diabetes, MASH, and obstructive sleep apnea endpoints. Regulatory approval is not yet in hand for any indication.
Read the full Retatrutide research guide →
Deep dive: Semaglutide
Semaglutide is a GLP-1 monoagonist developed by Novo Nordisk and approved by the FDA in 2017 (Ozempic, diabetes) and 2021 (Wegovy, obesity). The compound activates only the GLP-1 receptor, producing the canonical incretin effects of enhanced insulin secretion, slowed gastric emptying, and central appetite reduction.
The STEP-1 trial (Wilding et al., 2021) established the obesity outcome data: 14.9% mean body-weight reduction at 68 weeks with the 2.4 mg weekly dose. The trial was the basis for the Wegovy approval and established the GLP-1 monoagonist class as the new benchmark in obesity pharmacotherapy.
Aeternum Labs does not supply semaglutide for research; we focus on the triple-agonist class (Retatrutide) where the differential research signal is largest. We mention semaglutide here for cross-trial context only.
Read the full Semaglutide research guide →
Which should you research?
If your research is specifically about the next-generation triple-incretin class, Retatrutide is the focus. Phase 2 data positions it as the most potent member of the incretin family ever brought to human trials, and Phase 3 data will determine its regulatory trajectory.
If your research is in established GLP-1 monoagonist pharmacology, semaglutide is the reference compound — but we do not supply it for research. Most laboratories sourcing semaglutide do so through pharmaceutical specialty distributors rather than research peptide suppliers.
For comparative metabolic research that needs both compounds side by side, the triple agonist (Retatrutide) provides the differential signal against the published semaglutide reference data. Direct head-to-head trials are not yet publicly reported, but cross-trial comparisons consistently favor Retatrutide for total weight-loss magnitude.
Frequently asked questions
Why is Retatrutide producing larger weight loss than semaglutide?
The triple-receptor profile combines three complementary metabolic mechanisms: GLP-1 (insulin secretion + appetite), GIP (insulin sensitivity), and glucagon (energy expenditure + lipolysis). Semaglutide engages only the GLP-1 pathway. The additional GIP and glucagon arms contribute the additional ~10 percentage points of weight reduction observed in cross-trial comparisons.
Is glucagon agonism dangerous? It raises blood sugar.
Glucagon agonism on its own would worsen glycemic control. Retatrutide’s design pairs glucagon with strong GLP-1 insulinotropic activity, which more than compensates for the glucagon-induced hepatic glucose output. The net effect studied in published trials is improved glycemic control along with the metabolic and energy-expenditure benefits unique to glucagon receptor activation.
When will Retatrutide be FDA-approved?
Phase 3 trials are in progress under the TRIUMPH program. Regulatory submission timing depends on trial completion and data readouts. Public projections from Eli Lilly suggest potential approval in the 2025-2026 timeframe, but no guaranteed schedule has been published.
What dose ranges are used in Retatrutide research?
Phase 2 obesity research uses weekly subcutaneous doses ranging from 0.5 mg to 12 mg, with titration schedules from 2 mg/week up through 4 mg, 8 mg, and 12 mg in successive monthly increments to manage gastrointestinal tolerability.
Why doesn't Aeternum supply semaglutide?
Semaglutide is widely available through pharmaceutical specialty distributors and is not where our research-grade peptide focus adds the most differential value. Our catalog focuses on next-generation triple agonists (Retatrutide), other GH-axis and metabolic compounds, and tissue-repair peptides where the research-supplier path is the standard sourcing route.
References
- Jastreboff AM, Kaplan LM, Frías JP, et al. (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. View source
- Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP-1). View source
- Rosenstock J, Frias J, Jastreboff AM, et al. (2023). Retatrutide for type 2 diabetes: Phase 2 trial. View source
Reviewed by
The Aeternum Labs Research Team
Compounds, COAs, and protocol design
The Aeternum Labs research team verifies every batch in our library against published purity and identity standards. Comparison guides summarize publicly available scientific literature and are reviewed for accuracy by team members trained in peptide biochemistry.
Research Disclaimer. All compounds discussed in this article are sold by Aeternum Labs for in vitro laboratory research purposes only. They are not intended for human or animal consumption, diagnosis, treatment, or prevention of any disease or condition. Information presented is summarized from publicly available scientific literature and should not be construed as medical advice.